Search Results - "LANDERSDORFER, C. B"

Population Pharmacokinetic Comparison and Pharmacodynamic Breakpoints of Ceftazidime in Cystic Fibrosis Patients and Healthy Volunteers by BULITTA, J. B, LANDERSDORFER, C. B, HILTTNER, S. J, DRUSANO, G. L, KINZIG, M, HOLZGRABE, U, STEPHAN, U, SÖRGEL, F

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Comparable Population Pharmacokinetics and Pharmacodynamic Breakpoints of Cefpirome in Cystic Fibrosis Patients and Healthy Volunteers by BULITTA, J. B, KINZIG, M, LANDERSDORFER, C. B, HOLZGRABE, U, STEPHAN, U, SÖRGEL, F

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Evaluation of enrofloxacin use in koalas (Phascolarctos cinereus) via population pharmacokinetics and Monte Carlo simulation by Black, L. A, Landersdorfer, C. B, Bulitta, J. B, Griffith, J. E, Govendir, M

“…Clinically normal koalas (n = 6) received a single dose of intravenous enrofloxacin (10 mg/kg). Serial plasma samples were collected over 24 h, and…”
Get full text

New Semiphysiological Absorption Model To Assess the Pharmacodynamic Profile of Cefuroxime Axetil Using Nonparametric and Parametric Population Pharmacokinetics by BULITTA, J. B, LANDERSDORFER, C. B, KINZIG, M, HOLZGRABE, U, SORGEL, F

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Using machine learning to optimize antibiotic combinations: dosing strategies for meropenem and polymyxin B against carbapenem-resistant Acinetobacter baumannii by Smith, N.M., Lenhard, J.R., Boissonneault, K.R., Landersdorfer, C.B., Bulitta, J.B., Holden, P.N., Forrest, A., Nation, R.L., Li, J., Tsuji, B.T.

“…Increased rates of carbapenem-resistant strains of Acinetobacter baumannii have forced clinicians to rely upon last-line agents, such as the polymyxins, or…”
Get full text

Pharmacokinetics of polymyxin B in patients on continuous venovenous haemodialysis by Sandri, Ana M, Landersdorfer, Cornelia B, Jacob, Jovan, Boniatti, Márcio M, Dalarosa, Micheline G, Falci, Diego R, Behle, Tainá F, Saitovitch, David, Wang, Jiping, Forrest, Alan, Nation, Roger L, Zavascki, Alexandre P, Li, Jian

“…To evaluate the pharmacokinetics of polymyxin B in patients on continuous venovenous haemodialysis (CVVHD) after intravenous administration of unadjusted…”
Get full text

Shape does matter: short high-concentration exposure minimizes resistance emergence for fluoroquinolones in Pseudomonas aeruginosa by Rees, Vanessa E, Bulitta, Jürgen B, Nation, Roger L, Tsuji, Brian T, Sörgel, Fritz, Landersdorfer, Cornelia B

“…For fluoroquinolones, the area under the free plasma concentration-time curve divided by the MIC (fAUC/MIC) best predicts bacterial killing in mice and…”
Get full text

Evaluation of enrofloxacin use in koalas ( P hascolarctos cinereus ) via population pharmacokinetics and M onte C arlo simulation by Black, L. A., Landersdorfer, C. B., Bulitta, J. B., Griffith, J. E., Govendir, M.

“…Clinically normal koalas ( n  = 6) received a single dose of intravenous enrofloxacin (10 mg/kg). Serial plasma samples were collected over 24 h, and…”
Get full text

Reply to Pai by Landersdorfer, Cornelia B., Nation, Roger L., Forrest, Alan, Sandri, Ana M., Zavascki, Alexandre P., Li, Jian

Get full text

First-Dose Pharmacokinetics of Lithium Carbonate in Children and Adolescents by FINDLING, Robert L, LANDERSDORFER, Cornelia B, FABER, Jon, TAYLOR-ZAPATA, Perdita, JUSKO, William J, KAFANTARIS, Vivian, PAVULURI, Mani, MCNAMARA, Nora K, MCCLELLAN, Jon, FRAZIER, Jean A, SIKICH, Linmarie, KOWATCH, Robert, LINGLER, Jacqui

“…This study examines the pharmacokinetics of oral doses of lithium carbonate immediate-release capsules after administration of 600 or 900 mg in children and…”
Get full text